- Geometric mean titer of neutralizing antibody to live SARS-CoV-2 was 121 in the group who received the medium dose on days 0 and 14.
- Geometric mean titer of neutralizing antibody to live SARS-CoV-2 was 247 in the group who received the medium dose on days 0 and 21.
- Seroconversion was observed in 97.6% of volunteers in both groups from the phase two trial. 

Santa Clara University

Effectiveness of immunogenicity was assessed by measuring the geometric mean titer of neutralizing antibody to live SARS-CoV-2, and the geometric mean titer of specific IgG antibody to whole SARS-CoV-2 antigen. 
- Neutralizing Antibody Outcomes
- Specific IgG Antibody Outcomes

Immunogenicity Outcomes for the Inactivated Whole Virus Vaccine by Wuhan Institute of Biological Products Phase II Trial

Xia, S., Duan, K., Zhang, Y., Zhao, D., Zhang, H., Xie, Z., Li, X., Peng, C., Zhang, Y., Zhang, W., Yang, Y., Chen, W., Gao, X., You, W., Wang, X., Wang, Z., Shi, Z., Wang, Y., Yang, X., … Yang, X. (2020). Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA, 324(10), 951–960. https://doi.org/10.1001/jama.2020.15543

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials

Neutralizing Antibody Outcomes for the Inactivated Whole Virus Vaccine by Wuhan Institute of Biological Products Phase II Trial 

- The geometric mean titer of specific IgG antibody to a whole SARS-CoV-2 antigen for the medium dose group receiving the vaccine injection on days 0 and 14 was 74. Seroconversion was observed in 85.7% of the participants in this group. 
- The geometric mean titer of specific IgG antibody to a whole SARS-CoV-2 antigen for the medium dose group receiving the vaccine injection on days 0 and 21 was 215. Seroconversion was observed in 100% of the participants in this group. 

Learn Before

Related